KPNA2 and cholangiocarcinoma: In 32 patients with cholangiocarcinoma who received gemcitabine as an adjuvant chemotherapy or to treat recurrence, although KPNA2 overexpression tended to be a prognostic indicator of poor overall survival, there were no statistically significant differences (P = 0.06; Figure 2F).